
    
      This study is single arm study with DS-6051b in approximately 9 subjects with advanced solid
      malignant tumors harboring either a ROS1 or NTRK fusion gene. Safety and tolerability,
      pharmacokinetics (PK), maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) and
      preliminary efficacy of DS-6051b will be evaluated.
    
  